Distribution and Clinical Implication of CMD in Patients With HFpEF Without Significant CAD

Launched by SAMSUNG MEDICAL CENTER · Mar 5, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a condition called coronary microvascular dysfunction (CMD) in patients who have heart failure with preserved ejection fraction (HFpEF). This means that their heart pumps well but they still experience symptoms like shortness of breath, especially when they exert themselves. The goal of the study is to understand how common CMD is in these patients and what it might mean for their health outcomes. Participants will be evaluated to see if they meet certain criteria, like being at least 19 years old, having an ejection fraction above 50%, and showing symptoms of heart failure.

If you are eligible and choose to participate, you will undergo a coronary angiography, a test that helps doctors see how well blood flows through your heart's vessels. You will also need to sign a consent form to show that you agree to take part. The trial is currently recruiting participants of all genders, and it aims to provide important insights into how CMD affects people with HFpEF, which could help improve future treatments and care for heart failure patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject must be at least 19 years of age.
• • Subject with preserved ejection fraction (ejection fraction \> 50%)
• • Subject presented with dyspnea on exertion (NYHA Grade 2 or more) and diagnosed as HFpEF using HFA-PEFF scoring system (HFA-PEFF ≥5 or 2-4 with abnormal stress test or invasive hemodynamic test)
• • Subject who clinically need coronary angiography
• • Subject who is able to voluntarily sign informed consent form
• Exclusion Criteria:
• • Subject with reduced ejection fraction (\<50%)
• • Subject with significant coronary artery stenosis on coronary angiography (diameter stenosis ≥90% or 50-90% with fractional flow reserve \[FFR\] ≤0.80)
• • Subject who has other obvious causes of dyspnea (ex, lung disease)
• • Subject who have non-cardiac co-morbid conditions with life expectancy \<1 year